Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06377033 · ClinicalTrials.gov registry record · NA

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

A NA study of Alzheimer Disease and Parkinson Disease, sponsored by University of Pennsylvania.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
1
Study location

NCT06377033: Recruiting NA study of Alzheimer Disease and Parkinson Disease, sponsored by University of Pennsylvania.

NCT06377033 is a NA study of Alzheimer Disease and Parkinson Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 1,000 participants, below the 2,747-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06377033, a NA study of Alzheimer Disease and Parkinson Disease, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
1
Study location

Study Summary

Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place. Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dis

Primary Outcome

The number of patients seen by the total number of genetic tests conducted

Conditions Studied

Alzheimer Disease Parkinson Disease Frontotemporal Dementia ALS Genetic Predisposition Pheochromocytoma Paraganglioma Thoracic Aortic Aneurysm Polyneuropathies Cardiomyopathy Non-ischemic

Interventions

  • BEHAVIORAL Behavioral nudge

Study Locations (1)

Pennsylvania

  • Penn Medicine - Philadelphia

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-06-10
Est. Completion 2027-06-30
Phase NA
University of Pennsylvania

1,423 total trials

What NCT06377033 shows while recruiting

NCT06377033 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,747-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (64% lower).

The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Behavioral nudge is the first listed.

NCT06377033 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06377033 about?

NCT06377033 is a clinical study titled "Using the EHR to Advance Genomic Medicine Across a Diverse Health System". Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation a...

What is the current status of trial NCT06377033?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-06-10. Estimated completion is 2027-06-30.

What conditions does trial NCT06377033 study?

This clinical trial studies the following conditions: Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, ALS, Genetic Predisposition.

What interventions are being tested in trial NCT06377033?

The interventions under investigation include: Behavioral nudge (BEHAVIORAL).

Who is sponsoring clinical trial NCT06377033?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06377033 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06377033's enrollment target sits among peer trials

1,000 30th of 306 higher than 274 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06377033

Source: ClinicalTrials.gov NCT06377033, the US trial registry maintained by the National Library of Medicine. NCT06377033 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.